Chemours (CC) Expected to Announce Earnings on Monday

Key Points

• Chemours is expected to report Q3 2026 results on November 2, with analysts forecasting earnings of $0.2662 per share and revenue of $1.53 billion. In the prior quarter, the company missed consensus estimates on both earnings and revenue.
• Shares opened at $12.82, near the lower end of their 52-week range, while analysts maintain a consensus “Hold” rating and an average price target of $17.73. Chemours also pays a quarterly dividend of $0.0875 per share, equivalent to a 2.7% yield.
• Investors face additional uncertainty from reported securities-class-action allegations concerning Chemours’ 2026 guidance and weakening Opteon aftermarket demand; the claims have not been proven. The lead-plaintiff deadline is December 7, 2026.

Chemours (NYSE:CC - Get Free Report) is expected to be releasing its Q3 2026 results after the market closes on Monday, November 2nd. Analysts expect Chemours to post earnings of $0.2662 per share and revenue of $1.53 billion for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 2, 2026 at 8:00 AM ET.

Chemours (NYSE:CC - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The specialty chemicals company reported $0.42 earnings per share for the quarter, missing analysts' consensus estimates of $0.49 by ($0.07). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%. The company had revenue of $1.59 billion during the quarter, compared to analysts' expectations of $1.65 billion. During the same quarter in the prior year, the company earned ($2.54) EPS. The firm's revenue was down 1.5% compared to the same quarter last year. On average, analysts expect Chemours to post $0.83 EPS for the current fiscal year and $1.92 EPS for the next fiscal year.

Chemours Stock Up 0.0%

Shares of NYSE:CC opened at $12.82 on Monday. The company has a quick ratio of 0.88, a current ratio of 1.66 and a debt-to-equity ratio of 18.98. Chemours has a 52-week low of $10.44 and a 52-week high of $28.67. The company has a 50 day moving average of $14.46 and a two-hundred day moving average of $18.54. The company has a market capitalization of $1.93 billion, a price-to-earnings ratio of -6.71 and a beta of 1.41.

Chemours Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 15th. Stockholders of record on Friday, August 14th were given a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend was Friday, August 14th. Chemours's payout ratio is presently -18.32%.

Analyst Ratings Changes

Several brokerages have recently weighed in on CC. Mizuho restated a "neutral" rating and issued a $15.00 target price (down from $18.00) on shares of Chemours in a research note on Wednesday, October 14th. Zacks Research raised shares of Chemours from a "strong sell" rating to a "hold" rating in a research note on Thursday, September 10th. UBS Group dropped their price target on shares of Chemours from $18.00 to $16.00 and set a "neutral" rating on the stock in a research note on Monday, October 5th. Weiss Ratings lowered shares of Chemours from a "sell (d)" rating to a "sell (d-)" rating in a report on Thursday, August 6th. Finally, The Goldman Sachs Group reissued a "neutral" rating and issued a $16.00 price objective on shares of Chemours in a research report on Friday, October 9th. Three equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat.com, Chemours has a consensus rating of "Hold" and a consensus target price of $17.73.

Trending Headlines about Chemours

Here are the key news stories impacting Chemours this week:

• Negative Sentiment: Several law firms announced or promoted the same federal securities class action against Chemours and certain executives. The complaint covers investors who purchased CC securities from February 20 through August 4, 2026, and alleges that the company made material misstatements or omissions concerning the reliability of its financial guidance. The allegations have not been proven. Kessler Topaz securities-fraud lawsuit announcement
• Negative Sentiment: The complaint reportedly focuses on Chemours’ 2026 outlook and alleged failure to disclose that an oversupplied Opteon aftermarket channel was weakening demand. If sustained, the claims could create litigation costs, reputational risk and additional scrutiny of the company’s disclosures. SueWallSt Chemours class-action deadline alert
• Neutral Sentiment: Investors have until December 7, 2026, to apply to become lead plaintiff; the deadline is procedural and does not determine the lawsuit’s outcome or establish liability. Multiple alerts from ClaimsFiler, Pomerantz, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, Glancy Prongay and Frank R. Cruz largely repeat this information. Frank R. Cruz deadline alert

Insider Buying and Selling at Chemours

In other Chemours news, CFO Shane Hostetter bought 3,350 shares of the business's stock in a transaction on Thursday, August 6th. The shares were bought at an average cost of $14.94 per share, with a total value of $50,049.00. Following the transaction, the chief financial officer directly owned 102,698 shares in the company, valued at approximately $1,534,308.12. This trade represents a 3.37% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Calderon Gerardo Familiar bought 1,935 shares of the business's stock in a transaction on Wednesday, August 12th. The stock was acquired at an average cost of $15.53 per share, for a total transaction of $30,050.55. Following the completion of the transaction, the insider owned 58,547 shares in the company, valued at $909,234.91. This represents a 3.42% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 8,663 shares of company stock worth $130,601 in the last 90 days. 0.85% of the stock is owned by corporate insiders.

Chemours Company Profile

The Chemours Company NYSE: CC is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.